# A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

> **NCT05144984** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 500 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** NNC0480-0389
- **DRUG:** Semaglutide
- **DRUG:** Placebo (NNC080-0389)
- **DRUG:** Placebo (semaglutide)

## Key facts

- **NCT ID:** NCT05144984
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-29
- **Primary completion:** 2023-02-13
- **Final completion:** 2023-03-23
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05144984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05144984, "A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05144984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*